Lund Stem Cell Center’s Post

Liver cancer is the forth leading cause of death worldwide, accounting for more than 800,000 deaths each year. And over the next 20 years, the burden of primary liver cancer is expected to increase. Data from GLOBOCAN 2020, a platform that presents global cancer statistics, predicts that the incidence of liver cancer will increase by 55.0% and the number of deaths by 56.4% between 2020 and 2040. Primary liver cancer has therefore always been, and will continue to be a significant threat to global health. Adhering the strategy of early detection, early diagnosis and early treatment, hashtag #Snibe has developed a comprehensive liver cancer screening panel, l #Snibe #SnibeDiagnostic #LiverCancer #Healthcareforall #CancerScreening #immunoassay #biochemistry #diagnostics #diagnosis #bloodtest #histopathology #reagent #pathology #immunology #electrolyte #molecular #pointofcare #maglumi #cobas #architect #atellica #snibeuk

💾 Let's recap on groundbreaking advancements in cancer treatment and chemistry, showing how innovation is pushing boundaries in both fields shared by The Babak Lab this week. 💬 If you're interested in how science is driving real change, especially in critical areas like healthcare and elemental research, you’ll want to check this out. It’s a compelling read for anyone curious about the future of science and medicine!

🔴 Carl June, Richard W. Vague Professor in Immunotherapy in the University of Pennsylvania Perelman School of Medicine at the University of Pennsylvania, and director of the Parker Institute for Cancer Immunotherapy, has been selected as the winner of the IV Edition of the Abarca Prize for his pioneering research and development of a revolutionary strategy to treat blood cancers, based on cellular engineering. It is known as CAR-T cell therapy (Chimeric Antigen Receptor) and is an example of what is popularly known as immunotherapy treatment because it uses the body's own immune system tofight cancer. 👏👏 Congratulations!! In addition to this scientific finding of global relevance, his research continues to translate into other important clinical areas, as scientists are now working to apply this treatment to other solid neoplasms, autoimmune pathologies (such as lupus) and many other non-oncological diseases. The development of CAR T cell therapy is one of the most relevant medical-scientific advances of our time, comparable to the discovery of antibiotics, chemotherapy, or genetic research. More info about the winner at: https://lnkd.in/dQe9d4VC #AbarcaPrize2024 #medicalresearch #bloodcancers #CARTcelltherapy

Around one in 1,000 individuals is born with Down’s syndrome, a condition characterized by an extra copy of chromosome 21 (trisomy 21). Writing in Nature, Marderstein et al.1 examine the cellular and molecular features that predispose children with Down’s syndrome to a type of blood cancer called leukaemia. Single-cell multi-omics map of human fetal blood in Down syndrome Many developmental, behavioural and cognitive traits (phenotypes) have been reported in people with Down’s syndrome2. These individuals also face higher risks of developing conditions such as Alzheimer’s disease and childhood leukaemia, compared with the general population. Identifying the genes and molecular mechanisms that underpin susceptibility to these traits and diseases is complicated, because individuals with Down’s syndrome have 3 copies of more than 200 protein-coding genes, plus 3 copies of non-protein-coding elements such as RNAs, all of which vary in expression over time and between tissues and cell types. Marderstein and colleagues investigated where and how trisomy 21 perturbs the development of blood cells (haematopoiesis) during fetal growth, and how this puts children with Down’s syndrome at risk of developing myeloid leukaemia. During haematopoiesis, stem cells can differentiate into either myeloid-lineage cells — such as red blood cells, megakaryocytes (cells that form platelets) and cells of the innate immune system, including monocytes and macrophages — or lymphoid-lineage cells, such as T cells and B cells, which belong to the adaptive (acquired) immune system. Myeloid leukaemia is characterized by an overproduction of myeloid-lineage progenitor cells, especially the ones that give rise to red blood cells and megakaryocytes. Combining three single-cell-sequencing approaches, Marderstein and colleagues provide a comprehensive snapshot of individual trisomic blood cells and the cells that support them during early life. The authors examined gene expression (by assessing RNA transcription), control of gene expression by epigenetic mechanisms (by looking at the accessibility of DNA to the transcriptional machinery), and the spatial organization of these cells in the two main sites of blood-cell production during fetal development: the liver and the bone marrow.

🔴 Carl June, Richard W. Vague Professor in Immunotherapy in the University of Pennsylvania Perelman School of Medicine at the University of Pennsylvania, and director of the Parker Institute for Cancer Immunotherapy, has been selected as the winner of the IV Edition of the Abarca Prize for his pioneering research and development of a revolutionary strategy to treat blood cancers, based on cellular engineering. It is known as CAR-T cell therapy (Chimeric Antigen Receptor) and is an example of what is popularly known as immunotherapy treatment because it uses the body's own immune system tofight cancer. 👏👏 Congratulations!! In addition to this scientific finding of global relevance, his research continues to translate into other important clinical areas, as scientists are now working to apply this treatment to other solid neoplasms, autoimmune pathologies (such as lupus) and many other non-oncological diseases. The development of CAR T cell therapy is one of the most relevant medical-scientific advances of our time, comparable to the discovery of antibiotics, chemotherapy, or genetic research. #AbarcaPrize2024 #medicalresearch #bloodcancers #CARTcelltherapy

Functional heterogeneity of tumor-infiltrating B cells B cells have been long appreciated as an important component of tumor-infiltrating lymphocytes, but whether they play a positive or negative role in anti-tumor immunity is highly controversial. In this study, with comprehensive single-cell multiomic analyses of B cells across 20 cancer types, the researchers classified the tumor-infiltrating B cell responses into germinal center (GC)-like and extra-follicular (EF), with cancer type preference. They found that the EF B cell response was associated with an immunosuppressive tumor microenvironment (TME) and unfavorable prognosis. In contrast, the GC-like B cell response was linked with a fertile anti-tumor immunity and favorable outcome. In addition, through extensive analyses, the researchers determined the molecular feature and the differentiation pathway of the atypical memory (AtM) B cells (also called age-associated B cells, ABCs), the key player in the EF B cell response. Intriguingly, they found that the differentiation of AtM B cells could be promoted by glutamine metabolism, and the induced AtM B cells inhibited T cell functions and promoted Treg differentiation. #ScienceMission #sciencenewshighlights https://lnkd.in/gavQhSWG

Excellent work on the role of exercise and corticosteroids on cancer survival!  Our lab, ADDReB of Stanford Cardiovascular Institute, collaborated with Aida Habtezion and @Sid Sinha labs to develop a thermoreversible gel containing encapsulated Budesonide to treat ulcerative colitis. Our work is here: https://lnkd.in/g5inPpax Our lab also developed growth factors peptide analogues with Joseph C. Wu to increase stem cell survival. More details on this work are here: https://lnkd.in/gRmrJXDn The enigma of exercise in cancer prevention: Exercise produces IL6, a potent inflammatory protein, but amazingly, it prevents/ and improves cancer survival. The role of exercise on Il6/ cancer survival here: https://lnkd.in/g27ChEKR Euan Ashley interview on the benefits of exercise is here: https://lnkd.in/gmajZMZJ Details of the work on small molecules, including corticosteroids, and how they modulate immunity here: https://lnkd.in/gyG-gev8 # Benefits of exercise# cancer treatment # steroids # cancer prevention# Enhanced cancer remission

Congratulations to Drs. Anastasia Tikhonova and sushant kumar at University Health Network on receiving 2024 The Terry Fox Research Institute New Investigator Awards. Dr. Sushant Kumar has been named the Dr. Victor Ling Terry Fox New Investigator. This award distinguishes the highest-ranked Terry Fox New Investigator of the year. >> https://lnkd.in/gAYk7MgQ ----- Dr. Anastasia Tikhonova aims to optimize immunotherapy for acute lymphoblastic leukemia, a high-risk blood cancer developed in the bone marrow. She has identified that there are gaps in understanding how cytotoxic T cells interact with leukemia cells in the bone marrow, the site of disease progression. Gaining more insights on this area will generate innovative, more personalized treatments. >> https://lnkd.in/gQz4WAew Dr. Sushant Kumar leads a team to develop computational tools that leverage genetic sequencing to provide molecular insights for early cancer detection. To develop a proactive approach towards cancer, Dr. Kumar aims to use genomic analyses to identify genetic interactions between inherited and age-induced mutations critical for transforming a healthy tissue into a primary tumor. >> https://lnkd.in/gRgJEfB4 Research at UHN #cancerresearch #leukemia #researchaward

🚨 New Research Spotlight 🚨 Featured on the cover of Nature Cancer, this groundbreaking study unravels the immune biology of immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) and proposes potential treatment strategies beyond corticosteroids. 🔬 Key Findings: 1. Multiplex immunohistochemistry (mIHC) was crucial in identifying increased IL-17A expressing CD4+ T cells at the site of irAE inflammation in conditions like skin rash and colitis, providing a deep, spatial understanding of immune responses. 2. This aligns with serum proteomic analyses that revealed aberrant T cell activity and type I & III immune signatures, particularly in severe irAEs. Blocking IL-17A in patients with severe, corticosteroid-refractory irAEs led to a successful resolution of symptoms. 3. The use of mIHC in this study was instrumental in pinpointing key inflammatory cells, providing insight into the role of type III CD4+ T cells in irAE development, and supporting anti-IL-17A as a therapeutic target. 🎉 Congratulations to all the authors involved on this remarkable achievement and contribution to advancing immuno-oncology research! 🔗 :https://lnkd.in/eCPTd5GS #ImmunoOncology #NatureCancer #MultiplexIHC #CheckpointInhibitors #TheSpatialBiology #PhenoImagerHT #IL17A #ClinicalTrials #ScienceBreakthroughs #PhenomenalPublications

A deadly form of #ChildrensBrainCancer, #Immune to #Chemotherapy, is the target of new research looking at the #Epigenome and #ImmunoTherapies for answers. 🧠 #Paediatric high-grade #Glioma (pHGG) is the leading cause of disease-related death in children. Thanks to funding from the Medical Research Future Fund (MRFF) Dr Claire Sun will lead a team, including Dr Pouya Faridi as well as researchers from Children's Cancer Institute and Children's Medical Research Institute. Their research will make full use of our #ChildhoodCancerModelAtlas (#CCMA), a collection of more than 300 childhood cancer cell lines. 🧫 Read more about this research: https://bit.ly/3OWgUyQ Victorian Paediatric Cancer Consortium